Bid/Ask: Pfizer gains ac­cess to eczema suf­fer­ers; Ikea gets fru­gal in Europe

Bloomberg Businessweek (Asia) - - CONTENTS -

Pfizer snaps up Ana­cor Phar­ma­ceu­ti­cals. The pur­chase will give Pfizer con­trol of crisabo­role, an ex­per­i­men­tal treat­ment for eczema, a skin con­di­tion that af­fects as many as 25 mil­lion Amer­i­cans. If ap­proved by the U.S. Food and Drug Ad­min­is­tra­tion, the drug could reach an­nual sales of $2 bil­lion, ac­cord­ing to Pfizer. Palo Alto-based Ana­cor also holds the rights to Kery­din, a treat­ment for toe­nail fun­gus.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.